TESARO,Inc. (NASDAQ:TSRO) Files An 8-K Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial
Condition.

On May9, 2017, TESARO,Inc. (the Company) issued a press release
announcing its operating results for the quarter ended March31,
2017. A copy of the press release is attached to this current
report as Exhibit99.1 and is incorporated herein by reference.
TESARO,Inc. has scheduled a conference call and webcast for 4:15
p.m.Eastern time on May9, 2017 to discuss its operating results
for the quarter ended March31, 2017 and provide an update on the
Companys development programs.

The information contained in this report, including Exhibit99.1,
is being furnished to the Securities and Exchange Commission and
shall not be deemed to be filed for purposes of Section18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
or otherwise subject to liabilities under that section.
Furthermore, such information shall not be deemed to be
incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act, except as expressly set
forth by specific reference in such filing.

Section9 Financial Statements and Exhibits

Item 9.01 Financial Statements and
Exhibits.

(d) Exhibits.

About TESARO, Inc. (NASDAQ:TSRO)

TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.

TESARO, Inc. (NASDAQ:TSRO) Recent Trading Information

TESARO, Inc. (NASDAQ:TSRO) closed its last trading session up +1.02 at 137.89 with 849,559 shares trading hands.